Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Rhea-AI Summary

Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its fourth quarter and year-end 2024 financial results announcement for Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and recent corporate progress.

Investors can access the call via U.S./Toll-Free number +1 833 470 1428 or International number +1 404 975 4839 using passcode 126145. A webcast option is also available through the Events & Presentations section on Mirum's website, with a replay accessible for 30 days.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26, 2025. Mirum will also host a conference call to discuss the fourth quarter and year-end 2024 financial results and recent corporate progress.

Conference call details:

Wednesday, February 26, 2025

4:30 p.m. ET / 1:30 p.m. PT

Dial-in:

U.S./Toll-Free: + 1 833 470 1428

International: + 1 404 975 4839

Passcode: 126145

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI^® (maralixibat) oral solution, CHOLBAM^® (cholic acid) capsules, and CHENODAL^® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum's late-stage pipeline includes investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S. Lastly, Mirum is planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219189370/en/

Investor Contacts:

Andrew McKibben

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals (MIRM) release Q4 and full-year 2024 earnings?

Mirum Pharmaceuticals will release its Q4 and full-year 2024 financial results on Wednesday, February 26, 2025.

What time is MIRM's Q4 2024 earnings conference call?

The conference call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, February 26, 2025.

How can investors access MIRM's Q4 2024 earnings call?

Investors can access the call via U.S./Toll-Free number +1 833 470 1428 or International number +1 404 975 4839 using passcode 126145, or through the webcast on Mirum's website.

How long will MIRM's Q4 2024 earnings call replay be available?

The webcast replay will be available for 30 days following the earnings call.